Varicella Zoster Virus, Live Attenuated

Summary

Varicella Zoster Virus, Live Attenuated (CHEMBL6068357) is an approved vaccine component; indicated across 2 conditions including chickenpox.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Vaccine component
• Indications: 2 conditions
• Clinical trials: 20

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL6068357
Name	Varicella Zoster Virus, Live Attenuated
Type	Vaccine component
Max phase	4

Also known as: Varicella zoster virus, live attenuated, live attenuated component of proquad, Zostavax, VARICELLA ZOSTER VIRUS, LIVE ATTENUATED

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
chickenpox	4	MONDO:0005700	EFO:0007204

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 20.

Phase distribution

Phase	Trials
PHASE4	5
Not specified	4
PHASE3	3
PHASE1	3
PHASE2/PHASE3	2
PHASE2	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02444936	PHASE4	UNKNOWN	ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors
NCT02477150	PHASE4	COMPLETED	Safety and Immunogenicity of a Zoster Vaccine in SLE
NCT02958345	PHASE4	COMPLETED	Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™
NCT03016884	PHASE4	UNKNOWN	Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients
NCT04169009	PHASE4	COMPLETED	Persistence of Protection by Shingrix
NCT00561080	PHASE3	COMPLETED	Immunogenicity and Safety of a 1-dose Regimen of a Zoster Vaccine Versus Different 2-dose Regimens in Participants ≥ 70 Years of Age. (V211-043)
NCT01391546	PHASE3	COMPLETED	Immunogenicity and Safety Study of ZOSTAVAX Administered by Intramuscular or Subcutaneous Route to Participants Aged From 50 Years Old (V211-045)
NCT02329457	PHASE2/PHASE3	COMPLETED	VZV Vaccine for Hematopoietic Stem Cell Transplantation
NCT03116594	PHASE2/PHASE3	COMPLETED	Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
NCT03120364	PHASE3	COMPLETED	Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over
NCT00851786	PHASE2	COMPLETED	Live Zoster Vaccine in HIV-Infected Adults on Antiretroviral Therapy
NCT01213810	PHASE1/PHASE2	WITHDRAWN	Prevention of Varicella Zoster Virus (VZV)-Reactivation in HIV-positive Individuals Enrolled in a Prospective Immunogenicity and Safety Trial of VZV Vaccine: PROVE-IT-Study
NCT01573182	PHASE2	COMPLETED	Herpes Zoster Vaccine for Bone Marrow Transplant Donors
NCT01474720	PHASE1	COMPLETED	Zostavax in Systemic Lupus Erythematosus
NCT02114333	PHASE1	COMPLETED	Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
NCT03121638	PHASE1	COMPLETED	Safety Study of NBP608 in Healthy Adult Volunteers
NCT01328548	Not specified	COMPLETED	Zoster Vaccine Response in the Frail Elderly
NCT01331161	Not specified	COMPLETED	Systems Biology of Zoster Vaccine (ZOSTAVAX®) in Young and Elderly
NCT02704572	Not specified	COMPLETED	Optimal Timing of Zoster Vaccine After Zoster Illness
NCT03192319	Not specified	COMPLETED	Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).